 DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals Suzhou Co., Ltd. has received approval to market oral and intravenous IV formulations of XENLETA lefamulin for the treatment of community-acquired pneumonia CAP in adults in Taiwan. 